Newly Developed Prodrugs and Prodrugs in Development; an Insight of the Recent Years
Date
2020-02-17
Authors
Najjar, Anas
Najjar, Abderrahman
Karaman, Rafik
Journal Title
Journal ISSN
Volume Title
Publisher
MDPI
Abstract
Background: The design and development of prodrugs is the most common and e ective
strategy to overcome pharmacokinetic and pharmacodynamic drawbacks of active drugs. A respected
number of prodrugs have been reached the drugs market throughout history and the recent years
have witnessed a significant increase in the use of prodrugs as a replacement of their parent drugs
for an e cient treatment of various ailment. Methods: A Scan conducted to find recent approved
prodrugs and prodrugs in development. Results: Selected prodrugs were reported and categorized in
accordance to their target systems. Conclusions: the prodrug approach has shown many successes and
still remains a viable and e ective approach to deliver new active agents. This conclusion is supported
by the recent approved prodrugs and the scan of clinical trials conducted between 2013–2018.
Description
Keywords
ACT-281959 , ANAVEX 2-73 , baloxavir marboxil , clinical trial , evofosfamide , fostemsavir , ixazomib , pretomanid , prodrug , selexipag